NASH Biomarkers Market

Non-alcoholic steatohepatitis is an advanced stage of non-alcoholic fatty liver disease (NAFLD), which arises when the excess fat accumulation causes inflammation and damage leading to liver scarring. A biomarker is the most effective diagnosis tool for measuring the biological state and is termed as an indicator for measuring normal biological processes and pathogenic process in the body.

NASH Biomarkers Market contains market size and forecasts of NASH (Non-alcoholic Steatohepatitis) Biomarkers in global, including the following market information:

Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five NASH (Non-alcoholic Steatohepatitis) Biomarkers companies in 2021 (%)

The global NASH (Non-alcoholic Steatohepatitis) Biomarkers market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Serum Biomarkers Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of NASH (Non-alcoholic Steatohepatitis) Biomarkers include GENFIT SA, Gilead Sciences, Inc. (GILD), AstraZeneca, Novartis AG, Bristol-Myers Squibb Company, Allergan Plc, Novo Nordisk A/S, Boehringer Ingelheim and Pfizer Inc. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the NASH (Non-alcoholic Steatohepatitis) Biomarkers manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Segment Percentages, by Type, 2021 (%)

Serum Biomarkers

Hepatic Fibrosis Biomarkers

Apoptosis Biomarkers

Oxidative Stress Biomarkers

Others

Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Segment Percentages, by Application, 2021 (%)

Pharma & CRO Industry

Hospitals

Diagnostic Labs

Academic Research Institutes

Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies NASH (Non-alcoholic Steatohepatitis) Biomarkers revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies NASH (Non-alcoholic Steatohepatitis) Biomarkers revenues share in global market, 2021 (%)

Key companies NASH (Non-alcoholic Steatohepatitis) Biomarkers sales in global market, 2017-2022 (Estimated), (K Units)

Key companies NASH (Non-alcoholic Steatohepatitis) Biomarkers sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

GENFIT SA

Gilead Sciences, Inc. (GILD)

AstraZeneca

Novartis AG

Bristol-Myers Squibb Company

Allergan Plc

Novo Nordisk A/S

Boehringer Ingelheim

Pfizer Inc